雌二醇屈螺酮治疗妇女绝经后心悸症状疗效的系统评价

Systematic evaluation of estradiol drospirenone treatment on palpitation in postmenopausal women

目的 评价雌二醇屈螺酮治疗绝经后心悸症状的疗效.方法 通过检索PubMed、Science Direct、EBSCO Host、EMbase、The Cochrane Library、中国学术期刊全文数据库、万方数据库、维普中文科技期刊全文数据库,对纳入研究的方法学进行评价.研究者对纳入文献的质量进行严格评价和资料提取,使用Review manager 5.0软件对符合质量标准的随机分组对照临床试验（RCT）行系统评价.结果 13个RCT共纳入1 156例患者,其中治疗组650例,对照组506例,系统评价结果显示：采用雌二醇屈螺酮治疗绝经后心悸症状,相对雌激素替代疗法能显著提升疗效[相对危险度（RR）=-11.89、95％可信区间（95％ CI）-13.06～-10.72],相对安慰剂疗法能显著提升疗效（RR=-12.99、95％ CI-14.46 ～-11.52）.结论 雌二醇屈螺酮可显著改善绝经后心悸症状,值得推广.

Objective To evaluate the efficacy of estradiol drospirenone treatment on palpitation in postmenopausal women.Methods Retrieved nearly a decade PubMed,Science Direct,EBSCO Host,EMbase,The Cochrane Library,CNKI,Wanfang database,CQVIP.The evaluation methodology included.The researchers rigorously evaluated he quality of the included studies and extracted data,used the Review manager 5.0 software to meet the quality standards of randomized controlled clinical trials （RCT） line system evaluation.Results Thirteen RCTs were included 1 156 patients,506 cases in the control group,650 patients in the treatment group.The results of the evaluation of the system showed：estradiol drospirenone treatment could significantly improve the efficacy of postmenopausal symptoms,compared with hormone therapy [relative risk （RR） =-11.89,95% confidence interval （95 % CI）-13.06--10.72],versus placebo therapy （RR =-12.99,95%CI-14.46--11.52）.Conclusion Estradiol drospirenone can significantly enhance the efficacy of postmenopausal symptoms,be worthy of promotion.